Chronic Intestinal Pseudo-Obstruction from Anti-PD1/PDL1 Treatment
Author Information
Author(s): Zenatri Morgan, Collins Michael, Alberto Tifanie, Farina Antonio, Collardeau-Frachon Sophie, Saint-Jean Mélanie, Bocquet François, Dumont Frederic, Honnorat Jérôme, Joubert Bastien, Raimbourg Judith
Primary Institution: Institut de Cancérologie de L’Ouest
Hypothesis
Can vedolizumab be an effective treatment for chronic intestinal pseudo-obstruction induced by anti-PD1/PDL1 therapy?
Conclusion
Vedolizumab does not currently appear to be an effective treatment for chronic intestinal pseudo-obstruction induced by anti-PD1/PDL1 therapy, with only one patient showing transient improvement.
Supporting Evidence
- Vedolizumab was administered after corticosteroids failed in all three cases.
- Only one patient showed a transient improvement after treatment with vedolizumab.
- Chronic intestinal pseudo-obstruction is a rare and serious side effect of immune checkpoint inhibitors.
Takeaway
This study looked at three patients who had a serious stomach problem after cancer treatment. They tried a new medicine, but it didn't help much.
Methodology
Retrospective case study of three patients with chronic intestinal pseudo-obstruction treated with vedolizumab after corticosteroid failure.
Potential Biases
The retrospective nature of the study may introduce bias in the selection and reporting of cases.
Limitations
The study is based on only three cases, which limits the generalizability of the findings.
Participant Demographics
Three patients: two women aged 48 and 40, and one man aged 61, with varying cancer types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website